Glioma cell lines U251, U251 EGFR, U251 ΔEGFR, U87, and U87 ΔEGFR were subjected to treatment with erlotinib alone (0–40 μM) and combined with luteolin (10 and 20 μM). Here, EGFR is linked to central nervous system cancer.